登录新浪财经APP 搜索【信披】查看更多考评等级 瑞康医药集团股份有限公司（以下简称"公司"）于2025年7月3日披露了《关于公司董事、董事会秘书及 副总裁被采取留置措施的公告》（公告编号：2025-037），公司董事、董事会秘书及副总裁李喆先生被 实施留置措施。 证券代码：002589 证券简称：瑞康医药 公告编号：2026-002 瑞康医药集团股份有限公司 关于董事、董事会秘书及副总裁解除责令候查的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述和重大遗 漏。 特此公告。 瑞康医药集团股份有限公司 董事会 2026年2月13日 公司于2025年8月12日收到济南市济阳区监察委员会签发的《变更留置通知书》，已解除对李喆先生的 留置措施，变更为责令候查措施。详见公司2025年8月13日在巨潮资讯网（www.cninfo.com.cn）披露的 《关于公司董事、董事会秘书及副总裁解除留置并变更为责令候查的公告》（公告编号：2025-040）。 公司于2026年2月13日收到济南市济阳区监察委员会签发的《解除责令候查通知书》，已解除对李喆先 生的责令候查措施。目前公司生产经营 ...

北京商报讯（记者 丁宁）2月13日，瑞康医药（002589）发布公告称，公司于2月13日收到济南市济阳 区监察委员会签发的《解除责令候查通知书》，已解除对公司董事、董事会秘书及副总裁李喆的责令候 查措施。 瑞康医药表示，目前公司生产经营情况正常，李喆正常履职中。 ...

Group 1 - Ruikang Pharmaceutical received a notice from the Jinan Jiuyang District Supervisory Committee on February 13, lifting the investigation measures against its director, board secretary, and vice president Li Zhe, allowing him to resume normal duties [1] - ST Zhisheng's vice general manager, Lv Xuebin, has resigned due to work commitments at Sichuan University, and will no longer hold any positions within the company or its subsidiaries [1] - Wolong Nuclear Materials' H shares will be included in the Hong Kong Stock Connect securities list starting February 13, 2026 [1]

瑞康医药（002589）(002589.SZ)公告，公司于2026年2月13日收到济南市济阳区监察委员会签发的《解 除责令候查通知书》，已解除对李喆先生(公司董事、董事会秘书及副总裁)的责令候查措施。目前公司 生产经营情况正常，李喆先生正常履职中。 ...

智通财经APP讯，瑞康医药(002589.SZ)公告，公司于2026年2月13日收到济南市济阳区监察委员会签发 的《解除责令候查通知书》，已解除对李喆先生(公司董事、董事会秘书及副总裁)的责令候查措施。目 前公司生产经营情况正常，李喆先生正常履职中。 ...

证券代码：002589 证券简称：瑞康医药 公告编号：2026-002 瑞康医药集团股份有限公司 关于董事、董事会秘书及副总裁解除责令候查的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述和重大遗漏。 特此公告。 瑞康医药集团股份有限公司 董 事 会 2026 年 2 月 13 日 1 瑞康医药集团股份有限公司（以下简称"公司"）于 2025 年 7 月 3 日披露 了《关于公司董事、董事会秘书及副总裁被采取留置措施的公告》（公告编号： 2025-037），公司董事、董事会秘书及副总裁李喆先生被实施留置措施。 公司于 2025 年 8 月 12 日收到济南市济阳区监察委员会签发的《变更留置通 知书》，已解除对李喆先生的留置措施，变更为责令候查措施。详见公司 2025 年 8 月 13 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于公司董事、董事 会秘书及副总裁解除留置并变更为责令候查的公告》（公告编号：2025-040）。 公司于 2026 年 2 月 13 日收到济南市济阳区监察委员会签发的《解除责令候 查通知书》，已解除对李喆先生的责令候查措施。 ...

Group 1 - The core viewpoint of the news is that Ruikang Pharmaceutical has experienced a decline in stock price and financial performance, with significant changes in financing and shareholder metrics [1][2]. - On January 30, Ruikang Pharmaceutical's stock fell by 1.76%, with a trading volume of 210 million yuan. The financing buy-in amount was 15.07 million yuan, while the financing repayment was 23.70 million yuan, resulting in a net financing outflow of 8.63 million yuan [1]. - As of January 30, the total balance of margin trading for Ruikang Pharmaceutical was 244 million yuan, which accounts for 4.85% of its circulating market value, indicating a high level compared to the past year [1]. - The company has a significant margin balance, with a margin repayment of 5,700 shares and a margin sell-out of 5,200 shares on January 30, with a margin balance of 444,200 yuan, also at a high level compared to the past year [1]. - Ruikang Pharmaceutical's main business includes direct sales of pharmaceuticals (80.73% of revenue), medical devices (17.70%), mobile healthcare (0.67%), and other services [1]. Group 2 - As of October 31, the number of shareholders for Ruikang Pharmaceutical was 72,300, a decrease of 0.82% from the previous period, while the average circulating shares per person increased by 0.83% to 18,879 shares [2]. - For the period from January to September 2025, Ruikang Pharmaceutical reported a revenue of 5.407 billion yuan, a year-on-year decrease of 10.73%, and a net profit attributable to shareholders of 12.14 million yuan, down 68.73% year-on-year [2]. - Since its A-share listing, Ruikang Pharmaceutical has distributed a total of 393 million yuan in dividends, with 36.03 million yuan distributed over the past three years [3].

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.22% on January 29, with Renmin Tongtai leading the drop [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] Stock Performance - Notable gainers in the pharmaceutical sector included: - Run Da Medical (603108) with a closing price of 16.43, up 2.88% and a trading volume of 455,600 shares, totaling 756 million yuan [1] - Da Shen Lin (603233) closed at 20.25, up 2.27% with a trading volume of 84,100 shares, totaling 170 million yuan [1] - Hua Ren Health (301408) closed at 22.35, up 0.81% with a trading volume of 267,500 shares, totaling 602 million yuan [1] - Major decliners included: - Renmin Tongtai (600829) closed at 11.77, down 4.70% with a trading volume of 301,800 shares, totaling 357 million yuan [2] - Hai Wang Biological (000078) closed at 3.80, down 4.04% with a trading volume of 2,002,500 shares, totaling 771 million yuan [2] - Rui Kang Pharmaceutical (002589) closed at 3.40, down 2.86% with a trading volume of 757,500 shares, totaling 260 million yuan [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 310 million yuan from major funds, while retail investors contributed a net inflow of 388 million yuan [2] - The detailed capital flow for selected stocks showed: - Run Da Medical had a net inflow of 61.41 million yuan from major funds, but a net outflow of 44.17 million yuan from retail investors [3] - Kyushu Tong (600998) experienced a net inflow of 20.92 million yuan from major funds, with a net outflow of 7.80 million yuan from retail investors [3] - Other stocks like Da Shen Lin and Lao Bai Xing also showed mixed capital flows with varying degrees of net inflows and outflows [3]

Group 1 - The pharmaceutical commercial sector increased by 0.21% on January 26, with Haiwang Biological leading the gains [1] - The Shanghai Composite Index closed at 4132.61, down 0.09%, while the Shenzhen Component Index closed at 14316.64, down 0.85% [1] - Haiwang Biological's stock price rose by 9.95% to 4.20, with a trading volume of 2.84 million shares and a transaction value of 1.12 billion [1] Group 2 - The pharmaceutical commercial sector saw a net inflow of 6.12 million from institutional investors, while retail investors had a net inflow of 11 million [2] - Major stocks in the sector experienced varied performance, with some stocks like Hainan Biological and Ruikang Pharmaceutical showing significant gains, while others like Hefo China and Luhua Pharmaceutical faced declines [2][3] - The net inflow and outflow of funds indicate a mixed sentiment among different types of investors in the pharmaceutical sector [2][3]

Summary of Key Points Core Viewpoint - On January 20, Ruikang Pharmaceutical executed a block trade of 639,900 shares, amounting to 2.0797 million yuan, which represented 0.82% of the total trading volume for the day. The transaction price was 3.25 yuan, reflecting a discount of 6.07% compared to the market closing price of 3.46 yuan [1]. Group 1 - The block trade involved a total of 639,900 shares of Ruikang Pharmaceutical [2]. - The total transaction value for the block trade was 2.0797 million yuan [1]. - The transaction price of 3.25 yuan was 6.07% lower than the market closing price of 3.46 yuan [1].